Vertex Branches into Diabetes Field with Semma Therapeutics Acquisition

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 9 (Table of Contents)

Published: 7 Sep-2019

DOI: 10.3833/pdr.v2019.i9.2456     ISSN: 1756-7874

Section: Mergers & Acquisitions



Continuing to diversify its pipeline away from its flagship cystic fibrosis business, Vertex Pharmaceuticals has agreed to acquire Semma Therapeutics for US$950 M in cash...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details